CollPlant to add LightSolver CEO to board

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. (CLGN) reports that Dr. Ruti Ben Shlomi, Chief Executive Officer and Co-Founder of LightSolver Ltd., has been appointed to CollPlant’s Board of Directors, effective immediately following the completion of CollPlant’s acquisition of LightSolver, as announced on September 3, 2026.

The company explains that LightSolver develops pure photonic, laser-based high-performance computing technology using its proprietary Laser Processing Unit (LPU) to accelerate complex computational workloads. CollPlant describes this acquisition as expanding its activities beyond regenerative medicine into advanced high-performance and photonic computing, while it continues to focus on 3D bioprinting, tissue repair and medical aesthetics.

Key Terms

photonic computing, Laser Processing Unit (LPU), Physical AI, forward-looking statements, +1 more

5 terms

photonic computing technical

"establish photonic computing as a new computing layer"

Photonic computing uses pulses of light instead of moving electrons to carry out calculations and move information, like replacing electrical wiring with tiny beams of light on a computer chip. It matters to investors because light-based chips promise much faster data processing and lower power use for tasks like large-scale AI and data centers, potentially creating new markets and competitive advantages — but the technology is still emerging and carries development and scaling risks.

Laser Processing Unit (LPU) technical

"Its proprietary Laser Processing Unit (LPU), an energy-efficient, pure photonic computing"

Physical AI technical

"workloads across scientific simulation, engineering, optimization and Physical AI"

Physical AI combines artificial intelligence with physical devices or environments, enabling machines to interact with and adapt to the real world in a human-like way. It matters to investors because it can lead to smarter robots, autonomous vehicles, or advanced sensors that improve efficiency and open new markets, potentially creating significant business opportunities and competitive advantages.

forward-looking statements regulatory

"This press release contains forward-looking statements within the meaning"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

regenerative medicine medical

"CollPlant is a pioneering technology company operating at the forefront of both regenerative medicine"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

FAQ

What did CollPlant Biotechnologies (CLGN) announce in this Form 6-K?

CollPlant announced that Dr. Ruti Ben Shlomi, CEO and Co-Founder of LightSolver Ltd., has been appointed to its Board of Directors, effective immediately following completion of CollPlant’s acquisition of LightSolver.

Who is Dr. Ruti Ben Shlomi joining the board of CLGN, and what is her background?

Dr. Ruti Ben Shlomi is CEO and Co-Founder of LightSolver and an expert physicist with over 15 years of experience in quantum, atomic and molecular physics, photonic computing and technology leadership, including research at the Weizmann Institute of Science and prior work at Intel.

What does LightSolver contribute to CollPlant Biotechnologies (CLGN)?

LightSolver is described as pioneering high performance photonic computing via its proprietary Laser Processing Unit (LPU), an energy-efficient, pure photonic platform designed to accelerate computationally intensive workloads in scientific simulation, engineering, optimization and Physical AI.

How does the LightSolver acquisition change CollPlant’s business focus?

CollPlant states that, following the strategic acquisition of LightSolver, it has expanded into the deep-tech and high-performance computing sector, integrating LightSolver’s all-optical LPU architecture while continuing its core work in regenerative medicine, 3D bioprinting, tissue repair and medical aesthetics.

What future expectations does CollPlant (CLGN) highlight regarding LightSolver?

CollPlant includes forward-looking statements about the future development, commercialization and market adoption of LightSolver’s Laser Processing Unit technology and the growth opportunities and strategic rationale of the acquisition, while cautioning that results may differ due to various risks and uncertainties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 08:58 AM Accepted by SEC EDGAR 09/04/2026 - 08:58 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

On September 4, 2026, CollPlant Biotechnologies Ltd. issued a press release entitled “Collplant Appoints Dr. Ruti Ben Shlomi to Its Board of Directors Following Closing of Lightsolver Acquisition.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Attached hereto and incorporated by reference herein are the following exhibits:

99.1 Press Release, dated September 4, 2026.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: September 4, 2026	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

2

Exhibit 99.1

COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION

LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant’s Board as the Company advances the commercialization of its newly acquired photonic computing technology

REHOVOT, Israel, September 4, 2026 – CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced the appointment of Dr. Ruti Ben Shlomi, Chief Executive Officer and Co-Founder of LightSolver Ltd. (“LightSolver”), to CollPlant’s Board of Directors, effective immediately following the completion of CollPlant’s acquisition of LightSolver, as announced on September 3, 2026.

LightSolver is pioneering a new generation of high performance computing based on the physics of light. Its proprietary Laser Processing Unit (LPU), an energy-efficient, pure photonic computing platform that uses coupled lasers to perform computation, is designed to accelerate computationally intensive workloads across scientific simulation, engineering, optimization and Physical AI.

“We are delighted to welcome Dr. Ruti Ben Shlomi to CollPlant’s Board of Directors,” said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant. “Ruti is an accomplished physicist and entrepreneur whose pioneering work in photonic computing has established LightSolver at the forefront of deep-tech innovation. Her deep scientific expertise and entrepreneurial vision will be invaluable to our Board as CollPlant advances LightSolver’s commercialization and builds its position in high-performance and photonic computing.”

Dr. Ruti Ben Shlomi commented, “I am honored to join CollPlant’s Board of Directors as we begin this next chapter. The completion of this transaction creates an important opportunity to accelerate LightSolver’s transition from technology validation to commercialization and help establish photonic computing as a new computing layer for some of the world’s most demanding computational workloads. I look forward to working closely with the Board and executive team to as we advance this next phase of LightSolver’s development and create long-term value for our shareholders.”

Dr. Ruti Ben Shlomi is the CEO and Co-Founder of LightSolver. She is an expert physicist with over 15 years of experience spanning quantum, atomic, and molecular physics, photonic computing and technology leadership. Prior to co-founding LightSolver in 2020, Dr. Ben Shlomi conducted groundbreaking research at the Weizmann Institute of Science, where she built ultra-cold atom and cold ion systems to study complex quantum signatures. Earlier in her career, she served as a process engineer at Intel Corporation.

Dr. Ben Shlomi holds a Ph.D. in Quantum and Atomic/Molecular Physics from the Weizmann Institute of Science, an M.Sc. in Physics from Ben-Gurion University of the Negev, and a B.Sc. in Biophysics from Bar-Ilan University.

About CollPlant

CollPlant is a pioneering technology company operating at the forefront of both regenerative medicine and advanced high-performance computing. Following the strategic acquisition of LightSolver, CollPlant has expanded its footprint into the deep-tech sector, integrating a proprietary all-optical computing architecture known as the Laser Processing Unit (LPU). This bold diversification positions the Company to address some of the world’s most computationally intensive workloads across aerospace, defense, and Physical AI, while continuing to drive its core biotech innovations. 

In the healthcare sector, CollPlant is ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The Company’s products are based on its recombinant human collagen produced with CollPlant’s proprietary plant-based genetic engineering technology, addressing indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

For more information about CollPlant, visit www.CollPlant.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the acquisition of LightSolver by CollPlant; the anticipated benefits, strategic rationale and growth opportunities arising from the transaction; LightSolver becoming a subsidiary of CollPlant; the future development, commercialization and market adoption of LightSolver’s Laser Processing Unit (LPU) technology; and the future prospects, business plans and growth strategies of CollPlant, LightSolver and the combined business. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “continue” and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the following: the ability of the parties to satisfy the conditions to closing the transaction and consummate the transaction on the anticipated timeline or at all; the risk that the anticipated benefits of the transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver’s business, operations and personnel; LightSolver’s ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver’s technology; the ability to develop and commercialize LightSolver’s products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant’s ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contact Information:

CollPlant
  

Eran Rotem, Deputy CEO & CFO

Email: Eran@collplant.com

Tel: +972.73.232.5600

LightSolver Ltd.

Dr. Ruti Ben Shlomi, Founder & CEO

Email: Ruti@lightsolver.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE, DATED SEPTEMBER 4, 2026 11.9 KB